ARTICLE SUMMARY:
Reorganizing a major functional area at a large company is never easy, especially something as amorphous as innovation. Yet, that is exactly what J&J is undertaking, having convinced a leading cardiac surgeon to help lead the effort. Bruce Rosengard explains this new approach and how a clinical perspective can help enhance this process.
Innovation has always been the most highly prized currency of the medical device industry, so to hear a major player like Johnson & Johnson describe how they are re-prioritizing and restructuring how the company approaches innovation may sound as if they are re-stating the obvious.
